2021, Number 2
PDF size: 267.50 Kb.
Text ExtractionIn the still close December 2019, an epidemic outbreak produced by a coronavirus, later named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), emerged among the population of the Chinese city of Wuhan. On February 11 of 2020, the World Health Organization (WHO) designated with the acronym COVID-19 (Coronavirus Disease of 2019) the disease caused by SARS-CoV-2. The wide spread of COVID-19 led the WHO to recognize it a pandemic on March 11, 2020.
At a global scale, the efforts to halt the propagation of the still-young pandemic, and its very adverse sanitary, economic and social consequences, have been unsuccessful. As of March 28, 2021, the SARS-CoV-2 infection has reached 190 countries on all continents, leaving the unfortunate footprint of 126 372 442 infected people and 2 769 696 deaths.
World Health Organization. Coronavirus press conference, 11 February 2020. Geneva: WHO; 2020 [acceso: 16/02/2021]. Disponible en: Disponible en: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-full-press-conference-11feb 2020-final.pdf?sfvrsn=e2019136_2
World Health Organization. Virtual press conference on COVID-19, 11 March 2020. Geneva: WHO; 2020 [acceso: 16/02/2021]. Disponible en: Disponible en: https://www.who.int/docs/defaultsource/coronaviruse/transcripts/who-audio-emergencies-coronavirus-fullpress-conference-11feb2020-final.pdf?sfvrsn=e2019136_2
Abena P, Decloedt E, Bottieau E, Suleman F, Adejumo P, Sam-Agudu N, et al. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Am J Trop Med. Hyg. 2020;102:1184-8. DOI: https://doi.org/10.4269/ajtmh.20-0290
Gendrot M, Duflot I, Boxberger M, Delandre O, Jardot P, Le Bideau M. Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. Int J Infect Dis. 2020;99:447-54. DOI: https://doi.org/10.1016/j.ijid.2020.08.032
Gentry C, Humphrey M, Thind S, Hendrickson S, Kurdgelashvili G, Williams R. Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. Lancet Rheumatol. 2020;2:e689-97. DOI: https://doi.org/10.1016/S2665-9913(20)30305-2